Donna, That does explain things better but know that there are drug options out there. I think we all panicked because we realize 100 mg is not optimal at all. So it is scary when we hear that. I do understand the reasons for it now. You can switch for intolerability. I am on tasigna and have been since December. The initial start will require a lot of testing and monitoring but maybe they could put him in the hospital with it. It can cause QT Prolongation in some patients ( irregular heart beat). So he may not be a candidate. I would ask though. Also I have been put on 400 mg tasigna and I have basically NO side effects. Others like me are enjoying the same thing. I guess my best advice is to find out all you can and if your oncologists can't answer the questions for you, find new ones. The Novartis site will answer your questions for tasigna and I know there are trials going on at MDACC in Houston that he may be a candidate for. Many people I know are not responding to gleevec or intolerant of it are in trials there and doing well. They are on combo drugs, HHT and several new things coming down the pike.
Don't give up hope. Just educate. Find out your options and go with it. I am assuming his age is against a transplant as well. You might check out the MDACC site for drug trials. It is pretty easy to follow. If you want the info on tasigna let me know in a private email. I can attach the word docs I have. Bes of luck Donna and give my best to your positive guy!! I am sure there is a protocol out there that will have his name on it! Barb --~--~---------~--~----~------------~-------~--~----~ [CMLHope] A support group of http://cmlhope.com ------------------------------------------------- You received this message because you are subscribed to the Google Groups "CMLHope" group. To post to this group, send email to [email protected] To unsubscribe from this group, send email to [EMAIL PROTECTED] For more options, visit this group at http://groups.google.com/group/CMLHope -~----------~----~----~----~------~----~------~--~---
